找到相关结果： 957

Journal of Clinical Oncology: Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced PRCC

Toni K. Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, Eric Jonasch, Daniel Y.C. Heng, Thomas Powles, Melanie M. Frigault, Edwin A. Clark, Amir A. Handzel, Humphrey Gardner, Shethah Morgan, Laurence Albiges, and Sumanta Kumar Pal Abstract Pur

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-06-22

和黄医药在中国启动新型FGFR抑制剂HMPL 453的I/II期临床试验

1 个附件

2017年6月22日：和黄医药近日在中国启动HMPL-453的I/II期临床试验。HMPL-453是一种靶向成纤维细胞生长因子受体（FGFR）的新型高选择性小分子抑制剂。2017年6月19日首位受试者接受给药治疗。该�

下载新闻稿 (PDF)

公告及新闻稿, 监管通知 | 2017-06-16

Director’s Share Dealing

London: Friday, June 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- Dynamic Drive Limited, a person closely associated (“PCA”) with Mr Simon To, Executive Director and Chairma

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-06-12

和黄医药向国家食品药品监督管理局递交呋喹替尼治疗晚期结直肠癌的新药上市申请

1 个附件

–国家食品药品监督管理局已受理申请，并将由药品审评中心作技术审核– –将收到来自礼来共计3080万人民币的里程碑付款– 2017年6月12日：和黄医药今日宣布药物呋喹替尼�

下载新闻稿 (PDF)

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-06-05

和黄医药在ASCO年会上就呋喹替尼临床III期研究数据进行口头报告

1 个附件

2017年6月5日：和黄医药宣布在今天于美国芝加哥举行的美国临床肿瘤学会（ASCO）年会上就其自主研发的高选择性血管细胞内皮生长因子受体（VEGFR）抑制剂的关键III期临床研究结果进行了口�

下载新闻稿 (PDF)

演示文稿, 科学出版物 | 2017-06-05

ASCO 2017: Fruquintinib Phase III in Metastatic Colorectal Cancer (FRESCO)

A randomized, double-blind, placebo-controlled, multi-centered phase III trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO) Venue: American Society of Clinical Oncol

演示文稿, 科学出版物 | 2017-06-05

ASCO 2017: Sulfatinib Phase II in Medullary and Differentiated Thyroid Cancer

A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) Venue: American Society of Clinical Oncology Annual Meeti

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-05-18

和黄医药在ASCO 2017年会上公布临床数据

1 个附件

– 受ASCO组委会邀请口头报告呋喹替尼治疗结直肠癌的III期临床研究“FRESCO”的研究结果 – –将在大会上展示呋喹替尼，沃利替尼和索凡替尼共5项研究摘要 – 2017年5月18�

下载新闻稿 (PDF)

公告及新闻稿, 监管通知 | 2017-04-28

Total Voting Rights

London: Friday, April 28, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at April 28, 2017, the issued share capital of Chi-Med consisted of 60,735,104 ordinary sh

公告及新闻稿, 监管通知 | 2017-04-27

Results of Annual General Meeting

London: Thursday, April 27, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting (“AGM”) held on April 27, 2017 were duly

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-04-07

和黄医药在2017年AACR年会上公布呋喹替尼和索凡替尼的临床前数据

1 个附件

2017年4月7日：和黄医药在2017年4月1日至5日于美国华盛顿举行的美国癌症研究协会(AACR)年会上公布了呋喹替尼和索凡替尼的临床前数据。呋喹替尼和索凡替尼目前都在以多种癌症为适应症的III

下载新闻稿 (PDF)

演示文稿, 科学出版物 | 2017-04-04

AACR 2017: Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF-1R kinases

Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF-1R kinases Authors: Jinghong Zhou, Jun Ni, Min Cheng, Na Yang, Junqing Liang, Liang Ge, Wei Zhang, Jianxing Tang, Qiaoling Sun, Fu Li, Jia Hu,

演示文稿, 科学出版物 | 2017-04-03

AACR 2017: Fruquintinib combinations with targeted therapies or immune checkpoint inhibitors in preclinical tumor models

Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models Authors: Yongxin Ren, Qiaoling Sun, Jingwen Long, Shiming Fan, Renxiang Tang,

公告及新闻稿, 监管通知 | 2017-03-31

Total Voting Rights

London: Friday, March 31, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 31, 2017, the issued share capital of Chi-Med consisted of 60,715,323 ordinary sh

公告及新闻稿, 监管通知 | 2017-03-29

Vesting of awards under the Long Term Incentive Plan

公告及新闻稿, 监管通知 | 2017-03-28

Grant of Share Options under Share Option Scheme

London: Tuesday, March 28, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on March 27, 2017, it granted share options under the Share Option Scheme adopted by Chi-Med at its Annual General Meeting on April 24,

公告及新闻稿, 集团 | 2017-03-27

2016 Annual Report and Notice of Annual General Meeting

London: Monday, March 27, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2016 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders.

公告及新闻稿, 新闻稿, 集团 | 2017-03-24

Chi-Med Appoints Weiguo Su, Chief Scientific Officer, to Board of Directors

Appointment of Director London: Friday, March 24, 2017: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today announces that Dr Weiguo Su has been appointed as Executive Director and member of Technical Commi

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-03-21

Chi-Med to host R&D Briefings on March 29 & 30, 2017

Press Release London: Tuesday, March 21, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it will host Research & Development (“R&D”) briefings in London and New York to provide an overview o

公告及新闻稿, 监管通知 | 2017-03-20

Directors’ Share Dealing

London: Monday, March 20, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:- Mr Paul Carter, Independent Non-executive Director, purchased a total of 2,800 ordinary shares of US$1.00 each in

公告及新闻稿, 新闻稿, 集团 | 2017-03-16

Grant of Awards under Long Term Incentive Plan

Press Release London: Thursday, March 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on March 15, 2017, it granted conditional awards (“LTIP Awards”) under the Long Term Incentive Plan (“LTIP”) a

公告及新闻稿, 集团 | 2017-03-13

Publication of Form 20-F for the Year Ended December 31, 2016

London: Monday, March 13, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today published the Form 20-F for the financial year ended December 31, 2016 per attached and also available for viewing on the Company's website at ww

公告及新闻稿, 集团 | 2017-03-13

Chi-Med Reports Final Results for the Year Ended December 31, 2016 and Updates on Key Clinical Programs

Hutchison China MediTech Limited (“Chi-Med”) Reports Final Results for the Year Ended December 31, 2016 and Updates Shareholders on Key Clinical Programs Group: Record revenue, net income and clinical investment in 2016 Group revenue up 21%

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-03-10

和黄医药在欧洲神经内分泌肿瘤学会年会上公布索凡替尼治疗神经内分泌瘤Ib/II期临床试验结果

1 个附件

2017年3月10日：和黄医药在2017年3月8日至10日于西班牙巴塞罗那举行的第14届欧洲神经内分泌肿瘤学会年会（ENETS）上公布了索凡替尼正在进行的治疗晚期神经内分泌瘤的Ib/II期临床试验结果。�

下载新闻稿 (PDF)

演示文稿, 科学出版物 | 2017-03-09

ENETS 2017: Sulfatinib Phase Ib/II in Advanced Neuroendocrine Tumors

An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967) Authors: J.M. Xu, J. Li, C.M. Bai, N. Xu, Z.W. Zhou, Z.P. Li, C.C. Zhou, W. Wang, J. Li, C. Qi, Y. Hua, W.G. Su Summary: The current Phase

公告及新闻稿, 肿瘤学 / 免疫学 | 2017-03-03

和黄医药宣布呋喹替尼（HMPL-013）以局部晚期或转移性结直肠癌为适应症的III期临床试验“FRESCO”取得成功

1 个附件

–达到首要和次要终点 – – 安全性及疗效达到预期 – –计划于2017年中递交中国新药上市申请– –完整详细的试验结果将在2017年中通过肿瘤学术大会公布– 2017年3月3日：�

查看公告 (PDF)

公告及新闻稿, 新闻稿, 集团 | 2017-02-28

Chi-Med Appoints Graeme Jack as Independent Non-executive Director and Chairman of Audit Committee

Change of Directors London: Tuesday, February 28, 2017: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) today announces that with effect from March 1, 2017:- Mr Graeme Allan Jack has been appointed as I

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-02-20

Chi-Med Initiates a Phase II Study of Savolitinib in Pulmonary Sarcomatoid Carcinoma

Press Release London: Monday, February 20, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that a Phase II study of savolitinib has been initiated in locally advanced or metastatic pulmonary sarcomatoid carci

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-02-14

Chi-Med Initiates First-In-Human Clinical Trial of Novel FGFR Inhibitor HMPL-453 in Australia

London: Tuesday, February 14, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated the first-in-human (“FIH”) Phase I clinical trial of HMPL-453 in Australia. HMPL-453 is a novel, highly

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-02-14

Chi-Med and AstraZeneca Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium

Press Release London: Tuesday, February 14, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) and AstraZeneca PLC (“AstraZeneca”) will present data from the ongoing Phase II clinical trial of savolitinib in patients wi

公告及新闻稿, 监管通知 | 2017-02-06

Chi-Med to Announce 2016 Final Results

London: Monday, February 6, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its final results for the year ended December 31, 2016 on Monday, March 13, 2017 at 7:00 am Greenwich Mean Time (GMT). An analy

公告及新闻稿, 新闻稿, 集团 | 2017-02-01

Chi-Med Appoints Industry Veteran Karen Ferrante to Board of Directors

Change of Directors London: Wednesday, February 1, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that with effect from today:- Dr Karen Jean Ferrante has been appointed as Independent Non-Executive Director

演示文稿, 科学出版物 | 2017-01-20

ASCO GI 2017: Fruquintinib in Combination with Paclitaxel in 2L Gastric Cancer

A Phase I/II Trial of Fruquintinib in Combination with Paclitaxel for Second-line Treatment in Patients with Advanced Gastric Cancer Ruihua Xu, Dongsheng Zhang, Lin Shen, Jin Li, Jing Huang, Yang Zhang, Jifang Gong, Weijian Guo, Songhua Fan, Ke Li,

演示文稿, 科学出版物 | 2017-01-19

Journal of Hematology & Oncology: fruquintinib Phase Ib & Phase II in colorectal cancer

Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study Authors: Rui-Hua Xu, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin She

公告及新闻稿, 新闻稿, 集团 | 2017-01-16

Chi-Med Appoints Industry Veteran Paul Carter to Board of Directors

Change of Directors London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces with effect from February 1, 2017, Mr Paul Rutherford Carter has been appointed as Senior Independent Non-Execut

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-01-16

Chi-Med Initiates a Phase II Combination Study of Fruquintinib with Iressa® (gefitinib) in First-Line Non-Small Cell Lung Cancer

London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq:HCM) today announces that it has initiated a Phase II study of a combination therapy using fruquintinib and Iressa® in the first-line setting for patients

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-01-16

Chi-Med Initiates a Phase II Study of Sulfatinib in Second-line Biliary Tract Cancer in China

London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated a Phase II study of sulfatinib in second-line biliary tract cancer (“BTC”) patients in China. Sulfatinib

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-01-16

Chi-Med Presents Phase I/II Clinical Data for Selective VEGFR Inhibitor Fruquintinib at the 2017 Gastrointestinal Cancers Symposium

London: Monday, January 16, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from the ongoing Phase I/II clinical trial of fruquintinib in combination with paclitaxel (Taxol®) in second-line patients

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-01-10

Chi-Med Initiates HMPL-523 Clinical Trials in Hematological Cancer in China

London: Tuesday, January 10, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that it has initiated a Phase I trial of its novel spleen tyrosine kinase (“Syk”) inhibitor, HMPL-523, in patients with hematolo

公告及新闻稿, 监管通知 | 2016-12-30

Total Voting Rights

London: Friday, December 30, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 30, 2016, the issued share capital of Chi-Med consisted of 60,705,823 ordin

公告及新闻稿, 监管通知 | 2016-12-29

Blocklisting Six Monthly Return

London: Thursday, December 29, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: Hutchis

公告及新闻稿, 监管通知 | 2016-12-20

Director’s Share Dealing

London: Tuesday, December 20, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: CM) has received notification that Mr Simon To, Executive Director and Chairman, purchased a total of 17,839 American Depositary Shares of the Company (

公告及新闻稿, 监管通知 | 2016-12-14

Director’s Share Dealing

London: Wednesday, December 14, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Mr Simon To, executive Director and Chairman, purchased a total of 52,161 American Depositary Shares of the Compan

演示文稿, 科学出版物 | 2016-12-06

WCLC 2016: Fruquintinib Phase II Study in Advanced NSCLC

A Randomized, Multi-Center, Double-Blind Phase II Study of Fruquintinib in Patients with Advanced Non-Small Cell Lung Cancer (NCT02590965) Shun Lu1, Jianhua Chang2, XiaoQing Liu3, Jianhua Shi4, You Lu5, Wei Li6, Jinji Yang7, Jianying Zhou8, Jie Wa

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2016-12-06

Chi-Med Presents Pre-clinical Data for Selective Syk Inhibitor HMPL-523 at the 2016 American Society of Hematology Annual Meeting

Press Release London: Tuesday, December 6, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that data from a recent pre-clinical study, investigating the in vitro and in vivo anti-tumor activities of novel Spl

演示文稿, 科学出版物 | 2016-12-06

ASH 2016: Syk Inhibitor HMPL-523 Anti-tumor Activity in vitro and in vivo

HMPL-523, a Novel SYK Inhibitor, Showed Anti-tumor Activities in Vitro and in Vivo Na Yang, Wei Deng, Qiaoling Sun, Junqing Liang, Linfang Wang, Shiming Fan, Renxiang Tang, Ying Yu, Junen Sun, Feng Zhou, Guangxiu Dai, Yongxin Ren, Weiguo Qing and We

演示文稿, 科学出版物 | 2016-12-05

WCLC 2016: Epitinib in EGFRm+ NSCLC Patients with Brain Metastasis

A Phase Ib study of Epitinib to evaluate efficacy and safety in EGFR mutation positive (EGFRm+) NSCLC patients with brain metastasis Qing Zhou1, Bin Gan1, Qunying Hong2, Mengzhao Wang3, XiaoQing Liu4, Liwei Yuan5, Ye Hua5, Hongcan Ren5, Weiguo Su5,

公告及新闻稿, 监管通知 | 2016-11-30

Exercise of Share Options by a Person Discharging Managerial Responsibilities

London: Wednesday, November 30, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Dr Weiguo Su, Executive Vice President and Chief Scientific Officer (being a Person Discharging Managerial Respons

公告及新闻稿, 监管通知 | 2016-11-30

Total Voting Rights

London: Wednesday, November 30, 2016: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at November 30, 2016, the issued share capital of Chi-Med consisted of 60,703,323 or

公告及新闻稿, 监管通知 | 2016-11-23

Director’s Share Dealing

London: Wednesday, November 23, 2016: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Mr Michael Howell, Independent Non-executive Director, sold 10,000 ordinary shares of US$1.00 each in Chi-Med (the

1 2 3 4 5 6 7 8 9 10 11 12

14 15 16 17 18 19 20